◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › GILD

Gilead Sciences Inc (GILD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Biotechnology · DATA UPDATED 2026-07-12

Gilead Sciences Inc (GILD) operates in the Biotechnology industry and is headquartered in Foster City, United States with about 17,000 employees. Its market capitalization is roughly $161 billion. In the fiscal year ended 2025-12-31, GILD reported $29.4B in revenue and $8.5B in net income.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Interactive charts & full statements → Open the GILD valuation workbench →

GILD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$29.7B	$29.4B	$28.8B	$27.1B	$27.3B	$27.3B	$24.7B	$22.4B	$22.1B	$26.1B	$30.4B	$32.6B	$24.9B	$11.2B	$9.7B	$8.4B	$7.9B	$7.0B	$5.3B	$4.2B	$3.0B
Gross Profit	$23.6B	$23.2B	$22.5B	$27.1B	$21.6B	$20.7B	$20.1B	$17.8B	$17.3B	$21.7B	$26.1B	$28.6B	$21.1B	$8.3B	$7.2B	$6.3B	$6.1B	$5.4B	$4.2B	$3.5B	$2.6B
Gross Margin %	79.3%	78.8%	78.3%	100.0%	79.3%	75.8%	81.5%	79.2%	78.1%	83.3%	86.0%	87.7%	84.8%	74.5%	74.5%	74.7%	76.5%	77.2%	78.9%	81.8%	85.7%
Operating Income (EBIT)	$11.5B	$11.7B	$1.7B	$7.6B	$7.3B	$9.9B	$4.1B	$4.3B	$8.2B	$14.1B	$17.6B	$22.2B	$15.3B	$4.5B	$4.0B	$3.8B	$4.0B	$3.5B	$2.7B	$2.2B	($759M)
Operating Margin %	38.6%	39.7%	5.8%	28.1%	26.9%	36.3%	16.5%	19.1%	37.1%	54.1%	58.0%	68.0%	61.3%	40.4%	41.3%	45.2%	49.8%	50.3%	50.2%	51.2%	-25.1%
Net Income	$9.2B	$8.5B	$480M	$5.7B	$4.6B	$6.2B	$123M	$5.4B	$5.5B	$4.6B	$13.5B	$18.1B	$12.1B	$3.1B	$2.6B	$2.8B	$2.9B	$2.6B	$2.0B	$1.6B	($1.2B)
Net Margin %	31.0%	28.9%	1.7%	20.9%	16.8%	22.8%	0.5%	24.0%	24.6%	17.7%	44.4%	55.5%	48.6%	27.5%	26.7%	33.4%	36.5%	37.6%	37.1%	38.2%	-39.3%
EBITDA	$14.5B	$13.6B	$4.4B	$7.6B	$8.9B	$11.3B	$4.1B	$7.6B	$10.3B	$15.9B	$19.2B	$23.4B	$16.3B	$4.9B	$4.3B	$4.2B	$4.3B	$3.8B	$2.9B	$2.2B	$1.7B
Earnings Per Share (EPS)	$7.35	$6.78	$0.38	$4.50	$3.64	$4.93	$0.10	$4.22	$4.17	$3.51	$9.94	$11.91	$7.35	$1.81	$1.64	$1.77	$1.66	$1.41	$1.03	$0.84	$-0.65
Shares Outstanding (M)	1,254M	1,255M	1,255M	1,258M	1,262M	1,262M	1,263M	1,277M	1,308M	1,319M	1,358M	1,521M	1,647M	1,695M	1,583M	1,580M	1,747M	1,868M	1,918M	1,929M	1,836M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GILD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$7.0B	$7.9B	$7.8B	$7.1B	$6.7B	$7.6B	$7.5B	$7.0B
Gross Profit	$5.5B	$6.3B	$6.2B	$5.6B	$5.1B	$6.0B	$6.0B	$5.4B
Gross Margin %	79.2%	79.5%	79.8%	78.8%	76.9%	79.1%	79.1%	77.8%
Operating Income (EBIT)	$2.7B	$3.0B	$3.3B	$2.5B	$2.2B	$2.5B	$888M	$2.6B
Operating Margin %	38.7%	37.7%	42.8%	34.9%	33.6%	32.4%	11.8%	38.0%
Net Income	$2.0B	$2.2B	$3.1B	$2.0B	$1.3B	$1.8B	$1.3B	$1.6B
Net Margin %	29.0%	27.6%	39.3%	27.7%	19.7%	23.6%	16.6%	23.2%
EBITDA	$3.5B	$3.0B	$4.6B	$3.4B	$2.6B	$3.1B	$1.9B	$3.0B
Earnings Per Share (EPS)	$1.61	$1.74	$2.43	$1.56	$1.04	$1.42	$1.00	$1.29
Shares Outstanding (M)	1,254M	1,253M	1,254M	1,255M	1,259M	1,259M	1,254M	1,251M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GILD Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$10.8B	$10.0B	$10.8B	$8.0B	$9.1B	$11.4B	$8.2B	$9.1B	$8.4B	$11.9B	$17.0B	$21.2B	$12.8B	$3.1B	$3.2B	$3.6B	$2.8B	$3.1B	$2.1B	$1.8B	$1.2B
Capital Expenditures (CapEx)	$576M	$563M	$523M	$585M	$728M	$579M	$650M	$825M	$924M	$590M	$748M	$747M	$557M	$190M	$397M	$132M	$62M	$230M	$115M	$79M	$105M
Free Cash Flow (FCF)	$10.2B	$9.5B	$10.3B	$7.4B	$8.3B	$10.8B	$7.5B	$8.3B	$7.5B	$11.3B	$16.3B	$20.5B	$12.3B	$2.9B	$2.8B	$3.5B	$2.8B	$2.9B	$2.0B	$1.7B	$1.1B
FCF Margin %	34.4%	32.1%	35.8%	27.4%	30.6%	39.6%	30.4%	37.1%	33.8%	43.3%	53.6%	62.8%	49.3%	26.0%	28.8%	41.8%	34.9%	40.6%	38.0%	39.9%	36.8%
Dividends Paid	$4.0B	$4.0B	$3.9B	$3.8B	$3.7B	$3.6B	$3.4B	$3.2B	$3.0B	$2.7B	$2.5B	$1.9B	$6.4B	$1.7B	$2.4B	$4.7B	$3.1B	$400M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GILD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$2.5B	$3.3B	$4.1B	$827M	$1.8B	$3.0B	$4.3B	$1.3B
Capital Expenditures (CapEx)	$117M	$205M	$147M	$107M	$104M	$147M	$141M	$130M
Free Cash Flow (FCF)	$2.4B	$3.1B	$4.0B	$720M	$1.7B	$2.8B	$4.2B	$1.2B
FCF Margin %	34.9%	39.4%	51.0%	10.2%	24.8%	37.4%	55.2%	17.2%
Dividends Paid	$1.0B	$994M	$1.0B	$994M	$1.0B	$973M	$983M	$972M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GILD Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$56.3B	$59.0B	$59.0B	$62.1B	$63.2B	$68.0B	$68.4B	$61.6B	$63.7B	$70.3B	$57.0B	$51.8B	$34.7B	$22.6B	$21.2B	$17.3B	$11.6B	$9.7B	$6.9B	$5.8B	$4.1B
Cash & Cash Equivalents	$7.6B	$7.6B	$10.0B	$6.1B	$5.4B	$5.3B	$6.0B	$11.6B	$17.9B	$7.6B	$8.2B	$12.9B	$10.0B	$2.1B	$1.8B	$9.9B	$908M	$1.3B	$1.5B	$968M	$816M
Total Liabilities	$32.8B	$36.4B	$39.7B	$39.4B	$42.0B	$46.9B	$50.2B	$39.0B	$42.1B	$49.8B	$37.6B	$32.7B	$18.8B	$10.8B	$11.7B	$10.4B	$5.5B	$3.2B	$2.5B	$2.2B	$2.2B
Total Debt (Short + Long-Term)	$22.2B	$22.1B	$26.7B	$25.0B	$25.2B	$26.7B	$31.4B	$24.6B	$27.3B	$33.5B	$27.8B	$21.2B	$11.9B	$6.6B	$8.2B	$7.6B	$3.5B	$1.2B	$1.3B	$1.3B	$1.4B
Total Shareholders' Equity	$23.5B	$22.7B	$19.3B	$22.8B	$21.2B	$21.1B	$18.2B	$22.5B	$21.4B	$20.4B	$19.4B	$19.1B	$15.8B	$11.4B	$9.3B	$6.7B	$5.9B	$6.4B	$4.3B	$3.5B	$1.8B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GILD viewer.

Other Companies in Biotechnology

ABBV · AbbVie — $458 billion
AMGN · Amgen — $203 billion
VRTX · Vertex Pharmaceuticals — $121 billion
REGN · Regeneron Pharmaceuticals — $69 billion
BIIB · Biogen — $30 billion
ROIV · Roivant Sciences Ltd. — $26 billion
INSM · Insmed Incorporated — $26 billion
INCY · Incyte — $24 billion

← GIL All stocks GILT →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.